Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2010 1
2011 4
2012 4
2013 4
2014 11
2015 7
2016 3
2017 3
2018 4
2019 5
2020 12
2021 13
2022 4
2023 8
2024 4

Text availability

Article attribute

Article type

Publication date

Search Results

78 results

Results by year

Filters applied: . Clear all
Page 1
Pembrolizumab plus Chemotherapy in Advanced Endometrial Cancer.
Eskander RN, Sill MW, Beffa L, Moore RG, Hope JM, Musa FB, Mannel R, Shahin MS, Cantuaria GH, Girda E, Mathews C, Kavecansky J, Leath CA 3rd, Gien LT, Hinchcliff EM, Lele SB, Landrum LM, Backes F, O'Cearbhaill RE, Al Baghdadi T, Hill EK, Thaker PH, John VS, Welch S, Fader AN, Powell MA, Aghajanian C. Eskander RN, et al. N Engl J Med. 2023 Jun 8;388(23):2159-2170. doi: 10.1056/NEJMoa2302312. Epub 2023 Mar 27. N Engl J Med. 2023. PMID: 36972022 Free PMC article. Clinical Trial.
ATHENA (GOG-3020/ENGOT-ov45): a randomized, phase III trial to evaluate rucaparib as monotherapy (ATHENA-MONO) and rucaparib in combination with nivolumab (ATHENA-COMBO) as maintenance treatment following frontline platinum-based chemotherapy in ovarian cancer.
Monk BJ, Coleman RL, Fujiwara K, Wilson MK, Oza AM, Oaknin A, O'Malley DM, Lorusso D, Westin SN, Safra T, Herzog TJ, Marmé F, N Eskander R, Lin KK, Shih D, Goble S, Grechko N, Hume S, Maloney L, McNeish IA, Kristeleit RS. Monk BJ, et al. Among authors: n eskander r. Int J Gynecol Cancer. 2021 Dec;31(12):1589-1594. doi: 10.1136/ijgc-2021-002933. Epub 2021 Sep 30. Int J Gynecol Cancer. 2021. PMID: 34593565 Free PMC article. Clinical Trial.
Practice changing cervical cancer clinical trials.
Pothuri B, Eskander RN, Randall LM, O'Malley DM, Slomovitz B, Moore KN, Herzog TJ, Coleman RL, Copeland LJ, Monk BJ. Pothuri B, et al. Among authors: eskander rn. Gynecol Oncol. 2022 Jun;165(3):410-412. doi: 10.1016/j.ygyno.2022.03.004. Epub 2022 Apr 20. Gynecol Oncol. 2022. PMID: 35461731 No abstract available.
Recent Therapeutic Advances in Gynecologic Oncology: A Review.
Wilson EM, Eskander RN, Binder PS. Wilson EM, et al. Among authors: eskander rn. Cancers (Basel). 2024 Feb 13;16(4):770. doi: 10.3390/cancers16040770. Cancers (Basel). 2024. PMID: 38398161 Free PMC article. Review.
Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
Hill BL, Graf RP, Shah K, Danziger N, Lin DI, Quintanilha J, Li G, Haberberger J, Ross JS, Santin AD, Slomovitz B, Elvin JA, Eskander RN. Hill BL, et al. Among authors: eskander rn. Int J Gynecol Cancer. 2023 Apr 3;33(4):504-513. doi: 10.1136/ijgc-2022-004026. Int J Gynecol Cancer. 2023. PMID: 36750267 Free PMC article. Clinical Trial.
PARP Inhibitors in Epithelial Ovarian Cancer.
Taylor KN, Eskander RN. Taylor KN, et al. Among authors: eskander rn. Recent Pat Anticancer Drug Discov. 2018;13(2):145-158. doi: 10.2174/1574892813666171204094822. Recent Pat Anticancer Drug Discov. 2018. PMID: 29205122 Review.
78 results